See the DrugPatentWatch profile for Trospium
Trospium chloride's approval date varies by regulatory agency and specific formulation. In the United States, trospium chloride extended-release capsules (Sanctura XR) were approved by the Food and Drug Administration (FDA) in April 2007 [1]. Earlier, trospium chloride immediate-release capsules (Sanctura) received FDA approval in January 2005 [2].
When was Trospium Chloride first approved in Europe?
The European Medicines Agency (EMA) approved trospium chloride for the treatment of overactive bladder in adults. The brand name Sanctura was approved in the UK in 2003 [3].
What is Trospium Chloride used for?
Trospium chloride is an anticholinergic medication used to treat symptoms of overactive bladder, such as urinary urgency, increased frequency of urination, and urge incontinence [2]. It works by blocking the action of acetylcholine on the muscles of the bladder, allowing the bladder to relax and increasing its capacity [4].
How does Trospium Chloride work?
As an anticholinergic, trospium chloride blocks muscarinic receptors, particularly M2 and M3 subtypes, located in the detrusor muscle of the bladder [4]. By inhibiting the binding of acetylcholine to these receptors, it reduces involuntary bladder contractions, thereby alleviating the symptoms of overactive bladder [4].
What are the side effects of Trospium Chloride?
Common side effects associated with trospium chloride include dry mouth, constipation, blurred vision, and urinary retention [2]. Less common side effects may involve dizziness, drowsiness, and increased heart rate [2]. Patients with certain medical conditions, such as glaucoma, myasthenia gravis, or severe constipation, may not be suitable candidates for this medication [2].
What are the different formulations of Trospium Chloride?
Trospium chloride is available in both immediate-release and extended-release formulations. The immediate-release capsules (Sanctura) are typically taken twice daily, while the extended-release capsules (Sanctura XR) are taken once daily [1, 2]. The extended-release formulation aims to provide more consistent drug levels and potentially reduce some side effects by releasing the medication gradually over time [1].
What is the patent status for Trospium Chloride?
Information regarding the specific patent status and expiration dates for trospium chloride formulations can be found through patent tracking services. For instance, DrugPatentWatch.com provides data on drug patents, which can indicate when market exclusivity is set to expire [5].
How does Trospium Chloride compare to other overactive bladder medications?
Trospium chloride is one of several anticholinergic medications available for overactive bladder, alongside drugs like oxybutynin, tolterodine, and solifenacin. These medications differ in their receptor selectivity, pharmacokinetics, and side effect profiles. For example, some newer agents may offer improved tolerability compared to older anticholinergics [4].
Are there generic versions of Trospium Chloride available?
Following the expiration of patents and exclusivity periods, generic versions of trospium chloride have become available in various markets, potentially offering more affordable treatment options for patients [1, 2].
What are the clinical trial results for Trospium Chloride?
Clinical trials have demonstrated the efficacy of trospium chloride in reducing the frequency of micturition and the number of incontinence episodes in patients with overactive bladder [2]. Studies have also compared the extended-release formulation to the immediate-release version, showing similar efficacy with potentially improved adherence and tolerability for the extended-release form [1].
---
Sources:
[1] https://www.accessdata.fda.gov/drugsatfdadocs/label/2007/021663s007lbl.pdf
[2] https://www.accessdata.fda.gov/drugsatfdadocs/label/2005/021161lbl.pdf
[3] https://www.medicines.org.uk/emc/product/1993/pil
[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2851699/
[5] https://www.drugpatentwatch.com/